舒奈吡琼

{{Drugbox
| IUPAC_name = 1-{[2-(pyrimidin-2-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl}pyrrolidine-2,5-dione
| image = Sunepitron.png
| width =

| tradename =
| pregnancy_category =
| legal_status =
| routes_of_administration = 口服给药

| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =

| index2_label = HCl
| CAS_number_Ref =
| CAS_number = 131831-03-3
| CAS_number2_Ref =
| CAS_number2 = 148408-65-5
| UNII_Ref =
| UNII = 2GT50C8U60
| UNII2_Ref =
| UNII2 = 1NYW5HLO1E
| ATC_prefix = none
| ATC_suffix =
| PubChem = 9799246
| ChemSpiderID = 7975011
| KEGG = D02569
| ChEMBL = 380369
| synonyms = CP-93,393

| C=17 | H=23 | N=5 | O=2
| SMILES = O=C1N(C(=O)CC1)CC4CCC3N(CCN(c2ncccn2)C3)C4
}}

舒奈吡琼（INN：sunepitron；开发代号：CP-93,393）是一种5-HT1A受体激动剂和α2-肾上腺素受体拮抗剂的组合。辉瑞公司此前正在开发该药物，用于治疗抑郁症和焦虑症。它在停产之前进入了III期临床试验。

合成
参见

• 来索吡琼

参考资料